Truist Financial Corp Has $142.15 Million Holdings in Amgen Inc. $AMGN

Truist Financial Corp lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 434,301 shares of the medical research company’s stock after selling 37,080 shares during the quarter. Truist Financial Corp’s holdings in Amgen were worth $142,151,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Board of the Pension Protection Fund acquired a new stake in Amgen during the 4th quarter worth $26,000. Olistico Wealth LLC acquired a new stake in Amgen during the 4th quarter worth $33,000. Ares Financial Consulting LLC acquired a new stake in Amgen during the 4th quarter worth $34,000. Holos Integrated Wealth LLC acquired a new stake in Amgen during the 4th quarter worth $37,000. Finally, Cloud Capital Management LLC acquired a new stake in Amgen during the 3rd quarter worth $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $329.82 on Monday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 0.90. The stock has a market capitalization of $178.00 billion, a P/E ratio of 22.95, a P/E/G ratio of 3.24 and a beta of 0.44. The business has a 50-day moving average of $358.07 and a 200-day moving average of $341.12. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.28 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Analyst Ratings Changes

AMGN has been the topic of several research analyst reports. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Argus raised their price objective on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Daiwa Securities Group raised their price objective on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Truist Financial raised their price objective on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday. Finally, Rothschild & Co Redburn raised their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $357.54.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.